One in 8, or 12%, of adults said they have taken GLP-1s, and 6% of adults said they currently take the drugs, according to a May report from KFF.
In addition, in recent years, more prescriptions for GLP-1 drugs were written to treat obesity than Type 2 diabetes.
While the medications are growing in popularity, some insurance companies are skeptical of providing coverage.
Here are seven updates on insurance and GLP-1s:
1. Most health plans cover the diabetes medications, but weight loss indications and off-label prescribing are complicating insurance coverage. For a four-week supply, the list prices of GLP-1s approved for weight loss range between $1,050 and $1,350. After these drugs grew in popularity in late 2022, many commercial and state health plans slowed or stopped covering GLP-1s for weight loss. Demand has not ebbed. In 2023, the U.S. healthcare industry spent $38.6 billion on semaglutide (Ozempic, Rybelsus and Wegovy) and $13.2 billion on tirzepatide (Mounjaro and Zepbound). Compared to 2022, expenditures increased 100.1% and 373.1%, respectively.
2. Multiple health systems have removed weight loss drugs from their employer-sponsored plans, including West Orange, N.J.-based RWJBarnabas Health and Minneapolis-based Hennepin Healthcare. Austin-based University of Texas System, Bloomington, Minn.-based HealthPartners, Minneapolis-based Fairview Health Services, Rochester, Minn.-based Mayo Clinic and St. Louis-based Ascension have also trimmed coverage.
3. After the FDA approved Wegovy for certain heart conditions in March, Elevance Health, Kaiser Permanente and CVS Health expanded GLP-1 coverage. Sentara Health Plans did the same.
4. In March, The Cigna Group launched EncircleRx, a program aimed at helping employers control the cost of GLP-1 drugs for weight loss. Cigna describes EncircleRx as the “first-ever” GLP-1 management program with a financial guarantee for health plans. The program will cap yearly increases at 15%.
5. Cigna struck deals with GLP-1 manufacturers Eli Lilly and Novo Nordisk to help its initiative.
6. Insurance covers some of the costs for GLP-1 drugs for weight loss for around 1 in 4 Americans, according to data from Leverage and the Robert Wood Johnson Foundation.
7. In seven states, fewer than 1 in 10 have insurance coverage for new-generation weight loss drugs, including GLP-1s. Here is the percentage of insured individuals with coverage for weight loss drugs in each state.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
